19 research outputs found
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
Get PDFBig data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Get PDFCharacteristics and treatment patterns in patients newly diagnosed with chronic lymphocytic leukemia (CLL).
No full textSurvival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients.
No full textEconomic impact of rituximab as maintenance therapy in previously untreated follicular non-Hodgkin lymphoma.
No full textAssociation of skin rash severity and overall survival in patients receiving erlotinib for pancreatic cancer in the community setting.
No full textCost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL).
No full textAdherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
No full textIn this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
No full textIn this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab
Referral and Treatment Patterns Among Patients With Stages III and IV Non–Small-Cell Lung Cancer
No full text
